360 MD Austin
Austin, TX
Physician credentials on file
§ — Substance profile
α-MSH (11-13) · Lys-Pro-Val · Alpha-MSH C-terminal tripeptide
01 — Regulatory status
Regulatory status · United States · as of October 2026
Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. On July 23, 2026, the advisory committee voted 8–6 (one abstention) to recommend it for the 503A Bulks List, against the advice of FDA's scientists. FDA has not decided; it cannot yet be compounded under section 503A.
Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026
Reviewed October 2026 · Sources: FDA, EMA
02 — Researched for
Inflammatory bowel disease, skin inflammation.
03 — What the evidence shows
Anti-inflammatory effects in mouse colitis and cell models. No published controlled human trial.
04 — What is claimed but not shown
Treatment of IBD, eczema or systemic inflammation in humans.
05 — Known risks
Unknown in humans; unregulated sourcing.
06 — Researched for these goals
Related substances
07 — Questions for your physician
Every practice in the registry that lists peptide therapy, sorted by distance and nothing else. You contact the practice directly.
Austin, TX
Physician credentials on file
La Jolla, CA
No physician listed on the practice website
Chandler, AZ
Physician credentials on file
Alpharetta, GA
Physician credentials on file
San Francisco, CA
Ahvie Herskowitz, MD · Ann Lee, MD
Steamboat Springs, CO
Physician credentials on file
Listed for transparency, not as an endorsement of any practice, substance or protocol. Most peptides are not FDA-approved for the uses they are offered for.
Reviewed October 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.